Treatment of Hyperbilirubinemia Due to PEG-asparaginase and Inotuzumab Ozogamicin in Acute Lymphoblastic Leukemia (ALL)

clinical trial

Treatment of Hyperbilirubinemia Due to PEG-asparaginase and Inotuzumab Ozogamicin in Acute Lymphoblastic Leukemia (ALL) is …
instance of (P31):
clinical trialQ30612

External links are
P3098ClinicalTrials.gov IDNCT03564678

P6099clinical trial phasephase II clinical trialQ42824440
P17countryUnited States of AmericaQ30
P582end time2020-12-01
P921main subjectvitamin BQ183206
P1050medical conditionleukemiaQ29496
P2899minimum age12
P1132number of participants78
P4844research interventionfolic acidQ127060
vitamin BQ183206
asparaginaseQ421534
inotuzumab ozogamicinQ3799041
pegaspargaseQ7160547
P859sponsorThe University of Texas MD Anderson Cancer CenterQ1525831
P580start time2018-05-17
P8363study typeinterventional studyQ78089383
P1476titleMitochondrial Cofactors for the Treatment of Hyperbilirubinemia Due to PEG-asparaginase and or Inotuzumab Ozogamicin in Patients With Acute Lymphoblastic Leukemia (ALL)

Search more.